GRIL yields 151.52% · ABBV yields 3.06%● Live data
📍 GRIL pulled ahead of the other in Year 1
Combined, GRIL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GRIL + ABBV for your $10,000?
Muscle Maker, Inc. owns, operates, and franchises Muscle Maker Grill, SuperFit Foods meal prep, and Pokemoto Hawaiian Poke restaurants. The company operates a fast-casual restaurant that specializes in preparing protein-based meals featuring chicken, seafood, pasta, hamburgers, wraps, and flat breads, as well as entrée salads and sides, protein shakes, and fruit smoothies. It also operates under the Meal Plan AF, Muscle Maker Burger Bar, Bowls Deep, Burger Joe's, Wrap It Up, Salad Vibes, Mr. T's House of Boba, and Gourmet Sandwich brand names. In addition, the company offers Muscle Maker meal prep/plans to consumers through direct- to-consumer using musclemakerprep.com. As of December 31, 2021, it operated forty-two restaurants comprised of twenty-two company-operated restaurants and twenty franchised restaurants located in California, Florida, Georgia, Maryland, Massachusetts, New Jersey, New York, Connecticut, North Carolina, Oklahoma, Pennsylvania, Texas, Virginia, Washington, and Rhode Island, as well as in Kuwait. The company was incorporated in 2014 and is based in League City, Texas.
Full GRIL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.